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Abstract 
 
Background: The epidemic of type 2 diabetes poses an enormous 
and growing burden on health care globally. While the prevalence 
of diabetes is increasing worldwide, the developing countries 
will bear the greatest burden of this disease. Diabetes is one 
of the most common causes of kidney failure and nephropathy is a 
strong predictor of cardiovascular complications and death in 
these patients. Microalbuminuria represents a latent and early 
pre-symptomatic phase of nephropathy which can be stopped from 
progressing to an advanced stage if detected and treated early. 
The cost effectiveness of this screening and intervention has 
been researched and proven in the developed world, however 
similar studies in developing countries are non-existent. 
Microalbuminuria is not currently tested for in the public 
primary care sector. 
 
Aim and objectives: The aim was to assess the feasibility of 
introducing a screening test for microalbuminuria and the 
associated costs and consequences at Elsies River Community 
Health Centre (CHC) in the Metropolitan District of Cape Town. 
The objectives of the study are to assess the feasibility of 
implementing the test in our context, to assess any additional 
cost to the health services, to assess any measurable benefits 
in the quality of care for the patients, to extrapolate the 
likely long term consequences in terms of health outcomes, use 
of resources and costs and to make a policy recommendation to 
the Department of Health. 
 
Method: A cost and consequence study that describes the 
introduction of microalbuminuria testing in a cohort of type 2 
diabetic patients at Elsies River Community Health Centre, Metro 
District Health Services, Cape Town, South Africa. Point of care 
status analyser microalbuminuria screening was introduced to the 
CHC after training of the chronic care team, and their fidelity 
to the protocol measured. All patients who met the inclusion 
criteria were screened. Patients whose first results were 
abnormal had a repeat test after 3-6 months, if both results 
were abnormal patient was diagnosed microalbuminuria positive, 
however a patient with a second normal result required a third 
test. Interventions included addition of an Angiotesin 
Converting Enzyme inhibitor to their treatment, more intensive 
glycaemic, blood pressure or lipid control via medication or 
lifestyle changes and treatment adherence health education. 
Field notes were taken by the researcher during visits and a 
recorded focus group interview conducted with the health workers 
to explore their views on the feasibility of the screening and 
intervention. Cost was assessed by the estimation of the 
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additional resources required and the likely long term health 
outcomes extrapolated from available data and literature. 
 
Results: 15.2% of the sample population was noted to be 
microalbuminuria positive and they all received interventions. 
Additional cost required to screen a cohort of 100 patients was 
R1,109.40 per annum, out of which 15 patients at risk of 
developing nephropathy were identified and the cost of treating 
these patients was R1,393.20 for the first year. Qualitative 
data revealed that the test and interventions are feasible with 
an additional cost of staff time, medication and other materials 
which have been included in the cost above. 
 
Conclusion: This study represents the first attempt to 
successfully introduce screening for microalbuminuria in our 
public primary health care context. The chronic care team showed 
reasonable fidelity to the protocol and demonstrated the 
feasibility of screening and treating patients. The balance of 
costs and long term benefits suggests that this represents 
excellent value for money in a South African primary care 
setting.    
 
 
Introduction and background 
 
The epidemic of type 2 diabetes poses an enormous and increasing 
burden on health care globally.(1) It is estimated that the 
number of people with type 2 diabetes worldwide will rise from 
151 million in the year 2000 to 300 million by the year 2025.(2) 
Of particular concern is that most of the increase will occur in 
the developing world where the resources are scant and limited 
to deal with the problem.(1) 
 
Complications associated with diabetes are devastating to 
patients and lead to increased morbidity and mortality as well 
as premature death. Adults with diabetes have an annual 
mortality that is double that of their non-diabetic 
counterparts.(3) Diabetes is recognised as a major risk factor 
for cardiovascular and neurological complications that manifest 
as visual loss, leg ulcers, amputation, atherosclerosis, 
myocardial infarction, thromboembolism and stroke.(4) 
 
Diabetes is essentially a metabolic disease associated with the 
development of chronic kidney disease and cardiovascular 
complications. According to the World Health Organisation (WHO), 
about 50% of patients with diabetes mellitus will die from 
cardiovascular disease.(5) Well recognised is the significance 
of proteinuria as a risk marker for progressive deterioration in 
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kidney function.(6) The link between proteinuria or early kidney 
disease as an independent risk factor for cardiovascular 
morbidity and mortality has been established by meta-analysis of 
22 separate general population, cohort studies in older (>65) 
and younger people of different nationalities and races.(7) 
Early intervention can reduce chronic kidney disease progression 
and cardiovascular risk by 50% and consequently improve quality 
of life.(6)  
 
Microalbuminuria, defined as an increase in urinary albumin 
levels to between 20 and 200mg/L, represents elevated levels of 
urinary albumin that cannot be detected with standard urine 
dipstix analysis and is a reliable tool to identify and 
recognize early kidney damage.(8) Early screening and detection 
or diagnosis of microalbuminuria can lead to effective 
interventions to prevent progression and complications, 
particularly nephropathy and cardiovascular end points.(9) 
Detection of macroalbuminuria defined as urinary albumin levels 
above 200mg/L however is often too late to make as effective an 
intervention as nephropathy is already established.(9) It is of 
significant note that microalbuminuria (albumin excretion of 30-
300mg/day), unlike macroalbuminuria (albumin excretion of 
>300mg/day), is not considered to be synonymous with the 
presence of kidney disease as has been noted in recent analysis, 
because microalbuminuria is reversible if diagnosed and correct 
interventions commenced.(10,11) Microalbuminuria was found to be 
associated with carotid atherosclerosis in middle aged 
individuals, and has been shown to predict cardiovascular 
outcome in older individuals.(12) The Heart Outcomes Prevention 
Evaluation study, demonstrated that even a small increase in 
albuminuria increased the risk of cardiovascular events.(13) 
 
Currently public sector health centres in Africa only test 
patients for macroalbuminuria even though all the national, 
regional and international guidelines recommend testing annually 
for microalbuminuria.(14,15,16) The District Health Services 
have struggled to provide an adequate standard of care for 
diabetic patients and there have been doubts as to whether 
microalbuminuria testing is both feasible and affordable in our 
context.(17,18) This study therefore aims to explore the 
feasibility and costs of introducing the test at Elsies River 
Community Health Centre and to provide practical information for 
a policy decision on this issue.  
 
The World Health Organisation (WHO) principles of screening for 
disease which were published over four decades ago are excellent 
guiding principles for the introduction of a screening test and 
they are discussed in relation to diabetes and microalbuminuria 
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as follows: 
 
Diabetes is a common and important disease in our setting. 
 
There are no current or very recent national prevalence 
statistics for diabetes available in South Africa neither are 
there current information on the numbers or outcomes of patients 
with diabetic nephropathy. However based on the available 
epidemiological data, approximately 1-1.5 million South Africans 
are considered to have diabetes.(4) The South African National 
Burden of Disease Study reported that diabetes was the tenth 
leading cause of death among persons of all ages in 2000, 
accounting for an estimated 13,500 deaths (2.6% of the 
total).(4) In Cape Town up to 11% of the adult population is 
thought to be diabetic.(19) 
 
Nephropathy can be detected and prevented in a sub-clinical 
stage 
 
Nephropathy develops gradually in diabetic patients over a 
period of years. There is an early sub-clinical latent phase 
with the development of microalbuminuria being the first sign. 
After this the patient develops macroalbuminuria, which is a 
sign of more established disease and consequently patients may 
have a raised creatinine and low glomerular filtration rate. The 
patient is then likely to progress to a more advanced stage of 
kidney damage which may become chronic and eventually develop 
into end-stage renal failure.(20) Microalbuminuria is a sign of 
more widespread endothelial dysfunction and is also a predictor 
of complications elsewhere.(21) 
 
Microalbuminuria has been shown to be a strong predictor of 
progression to advanced stages of nephropathy, but can also 
regress with intensive blood glucose control, reduced serum 
lipids and lowered systolic blood pressure. In addition to the 
prevention of development of microalbuminuria, renal outcomes 
are improved after development of microalbuminuria with 
excellent control of glycaemia and blood pressure, even without 
the use of a Renin Angiotensin Aldosterone System (RAAS) 
inhibitor.(22) Angiotensin Converting Enzyme (ACE) inhibitors 
are particularly effective at reducing blood pressure and 
improving endothelial function with a reduction in albumin 
excretion.(16,23) The HOPE and the micro-HOPE studies showed 
that the reduction in microalbuminuria with ACE inhibitor 
Ramipril improved cardiovascular outcomes.(24,25) Effective 
inhibition of RAAS is demonstrated to provide renal protection 
in patients with type 1 and type 2 diabetes.(26) Systematic 
reviews showed that treatment with ACE inhibitors provide 
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significant reduction in albumin excretion rate in type 1 and 
type 2 diabetes. It was also shown that albumin excretion was 
reduced in normotensive diabetic patients and an increase in 
blood pressure was also prevented in the patients.(16) 
 
The potential benefits in terms of prevention outweigh the 
potential harms of ACE inhibitors in terms of adverse side 
effects, such as angio-oedema or anaphylaxis.(27) 
 
Microalbuminuria can be reliably detected in primary care 
 
Urinary albumin levels follow a circadian rhythm and are 
affected by many factors. A single positive test may be due to 
vigorous exercise in the last 24 hours, a fever, heart failure, 
urinary tract infections, prostatitis (in men) or even menstrual 
contamination (in women) and therefore a diagnosis of 
microalbuminuria is based on 2 positive tests on 2-3 separate 
occasions 3-6 months apart.(28) Results of a meta-analysis, 
comparing albumin-creatinine ratio in a random specimen to 
albumin excretion rate from a 24 hour sample; showed that the 
benefit of a 24 hour collection is small and not worth the cost 
and inconvenience.(28,29) Albumin measurement in a first morning 
urine are more reliable and more correlated with 24 hour protein 
excretion than measurement in a random spot urine sample for the 
diagnosis and monitoring of microalbuminuria.(28,32) Alternative 
methods of screening include timed (4 hour or overnight) urine 
collection, however the National Kidney Foundation guideline 
stated that it is usually not necessary to obtain a timed urine 
collection for evaluation of microalbuminuria, albumin should be 
measured in a spot urine sample using either an albumin specific 
dipstix or urinary albumin to creatinine ratio.(28-30)  
 
Several investigators and guidelines have advocated use of 
separate albumin creatinine ratio (ACR) cut off points for the 
detection of microalbuminuria in men and women of different 
racial groups.(33,34) This is because urine creatinine 
concentrations differ between men and women and between racial 
groups. Future research studies that use the ACR to define 
microalbuminuria should use sex specific ACR cut offs to help 
avoid the potential problems of underestimating microalbuminuria 
in subjects with higher urine creatinine excretion (e.g men) and 
overestimating microalbuminuria in subjects with lower urine 
creatinine excretion (e.g. women).(35) Microalbuminuria is 
hereby defined to be 17-250mg/g or 2.5-25mg/mmol and 25-355mg/g 
or 3.5-35mg/mmol in spot urine albumin-creatinine ratio in male 
and female patients respectively.(36) Screening for 
microalbuminuria has a sensitivity of 76% and a specificity of 
96%.(37) However sensitivities and specificities range between 
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69-96% and 41-97% respectively.(28) 
 
Microalbuminuria test is acceptable to the population 
 
The national kidney foundation(38) recommends the use of spot 
urine specimens obtained under standardised conditions (first 
voided morning midstream urine) to detect microalbuminuria and 
this may require the patient to collect the specimen bottle from 
the hospital and carefully collect the specimen at home and 
bring to the hospital on the day of visit. This is cumbersome, 
can be potentially unacceptable to patients and lead to poor 
compliance. Taking into consideration convenience, accuracy and 
cost, the measurement of urine albumin concentration in a random 
urine sample is the best choice for microalbuminuria screening 
in diabetic patients.(39) This makes the screening simple and 
readily acceptable to the patients as the specimen collected for 
the routine macroalbuminuria dipstix can be used for the 
microalbuminuria test.   
 
Microalbuminuria testing is cost-effective elsewhere 
 
Intensive treatment of microalbuminuria may stop chronic 
progression to end stage renal impairment and consequently 
reduce associated renal and cardiovascular morbidity and 
mortality with a potential decrease in overall costs of 
management.(41) Cost-effectiveness of screening for 
microalbuminuria has been researched in USA and Europe. 
Optimized treatment is associated with increased life 
expectancy, quality-adjusted life years and lifetime costs 
compared to conventional treatment. It has been shown that 
though it is more expensive to provide more intensive treatment, 
in the long run, it saves money on treating renal and 
cardiovascular complications, prolongs life and improves quality 
of life. Looking at the direct medical costs for intervention 
and control groups, it was projected that the cost was higher 
for intervention group. However, breakdown of costs revealed 
that incremental costs for the intervention group were less than 
those for the control group for all complications and 
interventions, despite patients living longer in the 
intervention group. The study showed that optimized treatment 
was cost-effective compared to conventional treatment.(9,42-44) 
The other alternative to screening for microalbuminuria and 
treatment of positive patients is the routine prescription of 
ACE inhibitor but it has been shown to be more costly than 
screening for microalbuminuria, albeit it is also cost effective 
as it increased Quality Adjusted Life Year (QALY) and life 
expectancy.(43) 
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Testing for nephropathy with microalbuminuria therefore meets 
all of the WHO criteria for secondary prevention which include 
the following: 
 Diabetes with diabetic nephropathy and cardiovascular 
complications is an important and common health problem. 
 There is a recognizable latent or early pre-symptomatic 
phase. 
 The natural history of the condition, including the 
development from latent to advanced disease is adequately 
understood. 
 There is a suitable test to detect the condition during 
this latent or pre-symptomatic phase.  
 No further diagnosis is required other than ensuring 2 out 
of 2-3 tests are positive. 
 The test is acceptable to the population. 
 There are effective interventions to treat the condition 
and prevent the development of nephropathy. 
 Early detection and treatment improves the final outcome.  
 The intervention has been shown to be cost-effective in 
other settings. 
 
The only remaining issues, which this study addressed, are 
whether it is feasible or practical in our public sector primary 
care setting and whether it is affordable.   
 
Aim 
 
The aim of this study was to assess the practicality of 
introducing a screening test for microalbuminuria and the 
associated costs and consequences at Elsies River Community 
Health Centre (CHC) in the Metropolitan District of Cape Town. 
 
Objectives 
 
 To assess feasibility of implementing the test in our 
context (i.e. can it be done within existing staffing 
levels and organization of care?) 
 To assess any additional cost to the health services (i.e. 
staff time, resources, equipment, changes in medication) 
 To assess any measurable benefits in the quality of care 
for the patients 
 To extrapolate the likely long term consequences in terms 
of health outcomes, use of resources and costs 
 To make a policy recommendation to the Department of Health 
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Study design 
 
A cost-and-consequence or cost and outcome study that describes 
the implementation of microalbuminuria testing on a cohort of 
type 2 diabetic patients in public sector CHC and evaluates the 
consequences for quality of care and the immediate costs 
involved. This can also be regarded as translational research – 
evaluating the implementation of evidence in clinical practice. 
 
Setting 
 
The study is part of a bi-centre study which is being conducted 
in the Metropolitan District of the City of Cape Town, South 
Africa. Elsies River CHC serves large numbers of diabetic 
patients from the uninsured population of Cape Town. Patients 
are mostly from low socio-economic backgrounds and historically 
disadvantaged black Xhosa speaking and coloured Afrikaans or 
English speaking communities. The other centre was Kraaifontein 
CHC which involved another MMed student who will report in a 
separate research assignment. 
 
Elsies River CHC runs diabetic “clubs”, on two days each week, 
Mondays and Thursdays, when diabetic patients are seen for 
review. Patients are seen 3 to 6-months depending on their 
glycaemic control. The diabetic clubs are run by teams of 
primary care providers (typically several nurses, 2 clinical 
nurse practitioners, a pharmacist and a health promoter), under 
the supervision of the family physician. The diabetic clubs are 
meant to perform the following tests and activities routinely on 
every patient: 
 Weight (every visit) 
 Body mass index (annually) 
 Blood pressure (every visit) 
 Urinalysis (every visit) 
 Random capillary glucose (every visit) 
 HbA1c (annually) 
 Cholesterol (annually) 
 Visual acuity and fundoscopy (annually) 
 Foot screening (annually and if at-risk every visit) 
 Education (every visit) 
 
Sampling procedure 
 
A disease register of all the diabetic patients attending the 
facility over a 6-month period was created and 581 patients were 
registered. Although the test was offered to all eligible type 2 
diabetic patients, a representative sample of 171 patients was 
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randomly selected from the disease register of 581 numbered 
patients using random numbers generated in an excel spreadsheet, 
to evaluate the screening process and this resulted in a 95% 
confidence interval that has a width/accuracy of 7.5% points. 
The records of all patients who screened positive for 
microalbuminuria from the total diabetic population of 581 were 
used to assess the implementation of interventions. 
  
The screening test, training and interventions 
 
Equipment for screening of microalbuminuria consisted of a 
point-of-care portable diagnostic machine (Status Analyser) and 
urine testing strips. Equipment and strips were donated by 
Siemens Medical Diagnostic Solutions. According to the 
manufacturer, the status analyser machine has a specificity of 
98.2%, sensitivity of 96.9% and the equipment calibrates itself 
automatically at intervals with a lifespan of about 5 years on 
average. 
 
The chronic care team was trained in the use of the equipment 
and how to interpret and act on the results. The researcher did 
help the team to plan a realistic organizational framework for 
testing, interpreting, recording and acting on the results at 
the clinic level. A standard operating procedure (SOP) was 
constructed for performing, interpreting and reacting to the 
test, full details are given in appendix 1. 
 
The routine urine dipstix for protein (macroalbuminuria) was 
done for each patient at the clinic. If negative, urine testing 
for the albumin:creatinine ratio (microalbuminuria) was then 
performed using the Status Analyser.  
If the ratio was normal, the test was repeated after one year.  
If the ratio was abnormal, a repeat urine test was performed at 
the second visit (when the patient next returns for a routine 
visit after 3-6 months as the case may be) and if the second 
test was negative a third test was performed at the third visit. 
Single testing is not reliable, but with multiple testing, 
reliability is improved to 98%. False positives may be seen in 
those with recent (last 24 hours) vigorous exercise, fever, 
heart failure, urinary tract infection, prostatitis (in male) 
and menstruation (in female, patients in these categories were 
excluded from the screening. The possibility of false positives 
is accounted for by repeated testing. 
It may take 3-6 months to perform the two tests and 6-12 months 
to perform all three tests, if this was necessary, as patients 
only attend every 3-6 months. 
If there was an abnormal result in two out of the three tests 
then the result for microalbuminuria was said to be positive and 
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this implies early renal disease. The clinic staff then 
attempted to improve overall diabetic control (glycaemia, 
lipids, weight, blood pressure). In particular the blood 
pressure should be reduced to the target of <130/80mmHg. If the 
patient was not on an ACE inhibitor this was started by the 
doctor or CNP. If the patient was already on an ACE inhibitor 
the need to increase the dose was considered. These 
interventions are in line with the published national and 
international guidelines for evidence-based practice and are not 
regarded as experimental.(6,9). 
Those who tested positive should have a repeat test after 
receiving the interventions for at least 12-months. 
 
The results of the microalbuminuria tests were recorded in a 
test register which was kept with the Status Analyser machine 
(Name, folder number, date and result of 1st, 2nd and 3rd 
tests), and the original result slip taken by the patient to the 
club room where it was attached to the chronic diseases summary 
sheet in the patient’s folder by the staff nurse. Testing was 
performed in the preparation room by a nurse and patients who 
tested positive for microalbuminuria were further managed by the 
clinical nurse practitioner (CNP). 
 
At the beginning, on-going support and supervisory visits by the 
researcher were done weekly (for one month) and then two-weekly 
(for two months). Once testing was established the researcher 
only visited monthly and as required. At these visits the 
researcher received feedback on the feasibility of performing, 
interpreting and responding to the test from the clinic staff 
and ensured that the protocol was being correctly followed. 
 
Assessment 
 
The disease register and the test register were used to select 
patients for different aspects of the assessment. 
 
Structural, process and outcome criteria were developed to 
monitor changes in the quality of care following the 
introduction of the test. This was to enable an assessment of 
how well the screening was implemented as well as the likely 
consequences in terms of additional resources used or required. 
Patients included in the study were followed up over the study 
period. A representative random sample selected from the disease 
register was used to evaluate the process and outcome criteria. 
Structural criteria were evaluated by the researcher at each 
clinic visit. Data was also recorded to give a profile of the 
diabetic patients. 
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Structural Criteria 
 
 SOP is in place for microalbuminuria testing 
 Microalbuminuria machine is in working order 
 Microalbuminuria testing strips available 
 Printing paper roll available 
 ACE inhibitor in stock 
 
Process criteria: 
 % of patients tested for macroalbuminuria 
 % of patients tested for creatinine 
 % of patients tested for HbA1c 
 % of patients tested for cholesterol 
 % of patients tested for microalbuminuria 
 % of patients with a positive first test  
 % of patients with a positive first test receiving a second 
test 
 % of patients with two tests (one negative / one positive) 
receiving a final test 
 % of patients with final results clearly recorded in the 
folder  
 
Outcome criteria: 
 % of patients with macroalbuminuria 
 % of patients with microalbuminuria 
  
Profile criteria: 
 Age and sex 
 % of patients with increased creatinine (>107mmol/l in 
Female & >115mmol/l in male) 
 % of patients with raised cholesterol (>5mmol/l) 
 % of patients with raised HbA1c (>7%) 
 Mean creatinine amongst those with no albuminuria, 
macroalbuminuria and microalbuminuria 
 Mean HbA1c amongst those with no albuminuria, 
macroalbuminuria and microalbuminuria 
 Mean systolic BP amongst those with no albuminuria, 
macroalbuminuria and microalbuminuria 
 Mean diastolic BP amongst those with no albuminuria, 
macroalbuminuria and microalbuminuria  
 
All those who tested positive for microalbuminuria were 
identified from the testing register and their folders examined 
to record information on the interventions that they received 
for the prevention of nephropathy and associated cardiovascular 
14 | P a g e  
 
complications. 
 % of patients with a final positive test result not on 
Angiotensin Converting Enzyme Inhibitor (ACEI) 
 % of patients with a final positive test receiving ACEI for 
the first time 
 % of patients with a final positive test already on ACEI 
 % of patients with a final positive test already on ACEI 
who have the dose increased 
 % of patients with a final positive test result receiving 
other additional treatment (dose increase or new 
medication) 
 % of patients with a final positive test result receiving 
additional health education or lifestyle advice 
 
The regular meetings with the chronic care team was recorded and 
used as qualitative data on the feasibility of introducing the 
screening test.  
The researcher also directly observed the screening process and 
noted any key positive or negative aspects of performing the 
test (i.e. time taken, mistakes made…). A focus group interview 
was held with the chronic care team at the end of the study 
period to explore their experience of using the new test. The 
interview was recorded, transcribed verbatim and then analysed 
as part of the qualitative data. Participants in the focus group 
interview were 8 in total, excluding the researcher; doctor 
(n=1) Clinical Nurse Practitioners (n=2), staff nurses (n=2), 
nursing assistants (2) and volunteer (n=1). The family physician 
directly supervises the CNPs on management and intervention, one 
of the staff nurses work in the club room sorting out the club 
patients, the other nurses work at different times in the 
preparation room while the volunteer (student of public health 
at the University of the Western Cape) helped with data 
collection most especially folder review. The length of the 
interview was 50 minutes and it was conducted in the quiet club 
room after the day’s work.  
 
The assessment of cost included the following data, which was 
reported on, in terms of additional costs required to test and 
treat 100 patients for a year: 
Status analyzer 
Testing strips and paper required to test all patients 1-3 times  
Additional medication used per month 
Additional staff time in minutes. 
 
The cost of identifying one person with microalbuminuria can 
also be calculated by dividing the cost of all the tests done by 
the number of diagnosed patients. 
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Data analysis 
MS Excel was used to capture the quantitative data and 
STATISTICA version 8 (StatSoft Inc. (2008) STATISTICA (data 
analysis software system), _ HYPERLINK "http://www.statsoft.com" 
_www.statsoft.com_.) used to analyse the data with the help of 
the Centre for Statistical Consultation.   
 
Summary statistics were used to describe the variables.  
Distributions of variables was presented with histograms and 
frequency tables. Means were used as the measures of central 
location for ordinal and continuous responses and standard 
deviations and quartiles as indicators of spread. 
 
The relationships between continuous variables and nominal 
variables were analysed using analysis of variance (ANOVA). A p-
value of p < 0.05 represented statistical significance in 
hypothesis testing and 95% confidence intervals were used to 
describe the estimation of unknown parameters.  
 
Recording of the team meetings were analyzed qualitatively using 
the framework approach and key themes relating to the 
feasibility and organization of care reported.(45) 
 
Extrapolation 
The likely impact of testing on secondary and tertiary level of 
care were extrapolated from the analysis. The likely long term 
costs and benefits in terms of testing, medication, preventing 
renal failure, avoiding dialysis, transplantation and hospital 
admissions were extrapolated using the literature and also based 
on a hypothetical cohort of 100 patients.  
 
Ethical consideration 
 
Relevant ethical issues for the study were: 
 
Permission: Ethical approval was obtained for the bi-centre 
study from the Health Research Ethics Committee of the Faculty 
of Health Sciences, University of Stellenbosch. The Western Cape 
Provincial Health Department granted permission for the study to 
be conducted in the two CHCs and the facility manager of Elsies 
River CHC permitted this study in her facility. 
 
Informed consent: Screening for microalbuminuria is already 
recommended by our national guidelines and therefore providing 
the test was aligned with normal and accepted standards of care 
and was in essence an expected improvement in the quality of 
care, it was not an evaluation of a new diagnostic test or a new 
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treatment. Therefore informed written consent for an 
experimental intervention from the patients was not necessary. 
No additional data was collected from patients beyond the usual 
clinical requirements and no patient identifiers were used in 
the analysis by the researchers. Clinic staff were required to 
explain the test to patients and obtain the usual level of 
verbal consent that is customary for a diagnostic test and the 
usual medical record. As with any diagnostic test patients could 
refuse. 
 
Written informed consent was obtained from the chronic care 
staff, who participated in the process and the interviews, 
details in appendix 2.  
 
Confidentiality: The disease register and testing register were 
kept and maintained by staff in the CHC and only used to sample 
patients. Data collection and subsequent analysis did not 
include any patient identifiers. Qualitative data from the 
chronic care staff were reported anonymously and names were 
excluded from the transcripts. 
 
Staff training: The adequate training of staff in performing the 
test, interpretation of the test, deciding on appropriate 
interventions and explanation of the test result to patients 
were of ethical necessity. The researcher provided training to 
everybody in the chronic care team. A SOP was provided for all 
these steps. 
 
Benefits and harms: Patients in the study benefited from a 
higher quality of care and possible prevention of chronic renal 
failure and cardiovascular complications. Patients might have 
been more motivated to engage with self-care activities as a 
result of the testing. Possible harms include false positive 
results leading to unnecessary interventions and worry regarding 
the possibility of renal disease.  However the interventions to 
improve control of diabetes would be indicated even without a 
positive result. Patients who had adverse reactions to ACE 
inhibitors that were started or increased, as a result of the 
test may experience harm. As ACE inhibitors were already widely 
used amongst diabetic patients these risks were not more than 
those faced by other diabetic patients. 
 
Conflict of interest: The status analyser equipment and packet 
of test strips donated by Siemens were used in the research 
project without fear or favour and the donation did not 
constitute any conflict of interest whatsoever. 
 
Results 
17 | P a g e  
 
 
Assessment of screening process 
 
This was based on a randomly selected sample of 171 patients 
from the 581 patients in the disease register. Out of these 
patients 42 (24.6%) were male and 129 (75.4%) were female. Their 
mean age was 59.9 years and the distribution of age is shown in 
Figure 1. 
 
Figure 1:  Age distribution of study sample (n=171) 
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Table 1 below presents a profile of key diabetes indicators in 
this diabetic population.  
 
Table 1: Profile of key diabetes indicators (N=171) 
Indicators N % 
Patients tested for HbA1c 99 57.9 
Patients with raised HbA1c (>7%) 81 47.4 
Patients tested for creatinine 113 66.1 
Patients with raised creatinine 21 18.6 
Patients tested for cholesterol 110 64.3 
Patients with raised cholesterol 63 36.8 
Mean Systolic Blood Pressure (mmHg) 146.0  
Mean Diastolic Blood Pressure (mmHg) 86.0  
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Overall 20 patients (11.7%) were noted to have macroalbuminuria 
and an additional 26 patients (15.2%) were diagnosed with 
microalbuminuria. Key indicators that describe the screening 
process are shown in Table 2. 
 
Table 2: Indicators of the screening process (N=171) 
 
Indicators N % 
Patients tested for macroalbuminuria 171 100.0 
Patients tested for microalbuminuria 151 88.3 
Patients with positive first test 57 33.3 
Patients with positive first test receiving a 
second test 
35 20.5 
Patients with 2 tests(one negative/one 
positive) receiving a final test            
3 1.8 
Patients with final results clearly 
recorded in the folder                      
171 100.0 
 
All patients were tested for macroalbuminuria and the number of 
patients tested for microalbuminuria was the total number of 
those eligible for the test 151/151 (100%), as the 20 patients 
with macroalbuminuria did not need to be tested. Of those who 
had a positive first test 35/57 (61.4%) received the necessary 
second test. This implies that 22/57 (38.6%) of patients were 
not screened completely at this stage. Ten patients were found 
to have an abnormal first test and a normal second test of whom 
3/10 (30.0%) received the necessary third test. Overall 
therefore 25/57 (43.8%) of patients with an initial abnormal 
result did not complete the screening process. 
 
Table 3 below shows the comparison of key diabetic indicators 
among patients with normal results, macroalbuminuria and 
microalbuminuria. There were no significant differences in 
diabetic indicators among the three groups, although the study 
was not designed to make this comparison. 
 
Table 3: Comparison of key diabetic indicators among those with 
normal results, macroalbuminuria and microalbuminuria 
Profile        Normal      Macro.     Micro.                 P-
values 
Mean creatinine                  78.8 100.9 91.8 0.8720 
Mean HbA1c                       
 
9.3        8.5       8.4         0.3868 
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Abbreviations: Macro = macroalbuminuria; Micro = 
microalbuminuria. 
 
The key results for the structural criteria are shown in Table 4 
below. Altogether structural criteria were evaluated at 25 
visits made to the facility during the study period. The result 
of the structural assessment were close to perfection, except 
for the status analyser machine that was reportedly faulty for a 
short period, only for the technician to discover that it was 
the newly inserted wrong size paper that was responsible. 
 
Table 4: Results for the structural criteria (N=25) 
 
Structure Frequency 
(n) 
% 
SOP in place for microalbuminuria screening 
and intervention                                  
25 100.0 
Microalbuminuria machine in working 
order/calibrated    
24 96.0 
Microalbuminuria testing strips available               25 100.0 
Microalbuminuria results printing paper 
available               
25 100.0 
Angitensin Converting Enzyme Inhibitor 
(Enalapril) in stock 
25 100.0 
Abbreviation: SOP=standard operating procedure 
 
The researcher observed during these visits that each test took 
an average of two minutes to do, while it took another 2-3 
minutes to record each result for the purpose of the study in 
the test register. The original results were then taken by 
respective patients to the club room. It took only a few seconds 
for the staff nurse in the club room to staple the original 
result to the chronic care summary sheet in the patient’s 
folder.  
 
Assessment of intervention in patients with microalbuminuria  
 
A total number of 74 patients were diagnosed with 
microalbuminuria as recorded in the test register. The 
interventions received by this group as a direct result of the 
diagnosis are described in Table 5. Data for two patients were 
Mean systolic BP                 145.5      144.5     150.1 
 
0.8964 
Mean diastoloic BP               86.0       84.3      82.5     
 
0.7327 
Mean cholesterol                 5.2       5.4       4.8 
 
0.7534 
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unavailable as one patient died and the other patient’s folder 
was missing. 
 
Table 5: Frequency of interventions on those who tested 
microalbuminuria positive (N=72)  
 
 
 
Intervention 
 
                               
Frequency(n)     
      
Percentage(%) 
 
 
Patients with final positive test 
result not on ACEI                                     
 
 
7
 
 
9.7
 
Patients with final positive test  
receiving ACEI for the first time               
 
 
36
 
 
50.0 
 
Patients with final positive test 
already on ACEI 
               
 
 
 
29 
 
 
 
40.3 
Patients with a final positive test  
already on ACEI who had the dose 
increased                                
 
 
28
 
38.9 
 
Patients with final positive test 
result 
receiving other additional 
treatment(dose 
increase or new medication)                                
 
 
 
 
23
 
 
 
 
31.9
Patients with final positive test 
result 
Receiving additional health 
education or lifestyle advice                    
 
 
 
40
 
 
 
55.6 
 
The table shows that the opportunity to initiate ACEI was missed 
in 9.7% of patients, while the benefits of ACEI were increased 
in 88.9% of patients. 
 
Cost analysis 
 
From the screening sample of 171 the total number of tests 
performed was 189. The total time spent in performing 189 tests 
and in identifying 26 positive patients was estimated as 378 
minutes. The cost of the intervention was based on the cost of 
additional medication and the staff’s extra time spent on 
education. It was estimated that 200 minutes in total (5 minutes 
per patient) was spent in educating the 40 patients. The cost of 
the analyser and strips to the public sector were quoted from 
the manufacturer as of May 2011, while the cost of the paper was 
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the retail cost as of August 2011. The cost of the staff time 
was based on the salary scale of full time clinical nurse 
practitioner (for education) and staff nurse (for testing) grade 
one, notch one (new OSD salary notches/total ‘CTE’ packages on 1 
July 2010) while the cost of additional medication was based on 
the cost as purchased by Metro District Health Service (MDHS) in 
August 2011. The amount and cost of the additional medication 
for the 72 patients diagnosed from the total disease population 
is shown in Table 6. 
 
Table 6: Additional prescriptions and costs per month 
 
Medication Dose 
started 
or 
added 
Cost 
per 
month 
(rands) 
Number of 
prescriptions 
Total cost 
(rands) 
Enalapril 5mg BD  4.96 35 173.60 
 10mg BD  5.36 27 144.72 
 15mg BD 10.32 2  20.64 
Amlodipine 5mg  2.99 2   5.98 
 10mg  4.99 2   9.98 
Hydrochlorothiazide 12.5mg  2.26 2   4.52 
Gliclizide 40mg BD  5.66 3  16.98 
Metformin 850mg  3.96 3  11.88 
Protophane 10 Unit 24.55 2  49.10 
  2 Unit  1.60 2   3.20 
Simvastatin 10mg  3.94 9  35.46 
                                          Total     476.06 
 
Table 7 summarises the additional costs of the screening process 
based on the 171 patients sampled and the actual performance 
achieved in this health centre. It was assumed that the analyser 
would last for a period of five years before replacement and 
during this study a total of 581 patients were screened over a 
12 months period. The proportion of the cost for 171 patients 
could therefore be calculated. 
 
Table 7: Cost of screening process 
 
Item Cost 
Portion of capital cost of analyser  901.00 
189 test strips 949.54 
Rolls of printing paper for analyser   4.50 
378 minutes of staff nurse time for screening  68.04 
Total cost to screen 171 patients 1923.08 
Total cost to screen 100 patients 1124.61 
Total cost to identify one patient with microalbuminuria   73.96 
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Table 8 summarises the additional costs of the intervention for 
the first month. This was based on the 72 patients diagnosed in 
this study and according to the level of performance obtained in 
this health centre. It was assumed that additional health 
education took on average 5 minutes and was given by a clinical 
nurse practitioner. 
Table 8: Cost of the interventions 
 
Item Cost 
(Rands) 
 
Cost of additional medication 476.06 
200 minutes of CNP time for education  81.26 
Cost of intervention for 72 patients 557.32 
Cost of intervention for 100 patients 774.06 
Cost of intervention for 1 patient   7.74 
Cost of intervention for 1 year per patient  80.50 
 
 
Qualitative Data Analysis   
 
The staff needed to be motivated before the screening process 
could take off and the first few weeks of the study was eventful 
as a lot of mistakes were made in performing the test, but this 
was largely due to repeated replacement of the staff nurses in 
the preparation room with new nurses that warranted repeated 
training of the nurses. It ended as an advantage as many nurses 
in the facility became more aware of the programme and some of 
them became expert in the process and later helped in training 
others. However some patients were missed because patients threw 
away their urine specimen while the nurse was busy with their 
dipstix macroalbuminuria test as clear instructions were not 
given by the nurse. Individual meetings of the researcher with 
every member of the chronic care team, collaboration with the 
family physician at the facility and the power point 
presentation at the start of the research served as strong 
motivation to the staff of the CHC. By the end of the first 
month the team adapted the screening to their daily routine to 
the extent that it was difficult to convince them to stop the 
process at the end of the research period. The CNPs involved 
with the interventions were the most motivated, they used their 
cell phones to call me sometimes when they needed to seek 
clarification on certain aspects of the management especially 
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when the only patient with intolerable cough due to Enalapril 
presented to the facility. 
 
The following themes were derived from the focus group interview 
and regular meetings with the chronic care team. 
 
1a: Ease and feasibility of doing the test 
 
Respondents reported that the test was easy to do and could be 
introduced into the primary care practice. They appreciated the 
benefits the patients will derive from the introduction of this 
test: 
“I think it is feasible, to prevent renal failure in the long 
term. To pick it up if there is any protein in the urine or not, 
so the doctor can start immediately with treatment on the 
patient.” 
“I think to the people that are involved in this whole exercise 
it is feasible, there is no doubt about it because even the ones 
who have come so far you can see the result for yourself and 
overall it’s the patient that will benefit.” 
 
1b: Ease and feasibility of interpreting and acting on the 
result 
 
The respondents involved with interpretation and intervention 
also recognised the importance of introducing the test and so 
they also believed that it was easy and feasible: 
“It’s actually very easy because the patients know themselves 
that if they are diabetic their heart and their kidneys are at 
stake, so it’s much easier to explain it to them that this 
treatment is something that will prevent them to get into renal 
failure in the future. Most of them do understand it and it’s 
only a few patients, a little number that are negative towards 
it.”  
 
2a: Time required for carrying out the test 
 
Participants in the preparation room did spend significantly 
more time on patients who are eligible for the test and this is 
quantified as five minutes which was inclusive of time spent in 
documenting the result in test register for the purpose of the 
study: 
“It takes about 5 minutes, may be less but let’s keep it at 5 
minutes.” 
 
2b: Time required for interpreting and acting on the result 
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CNPs believed the time spent acting on the positive result was 
small and did not significantly increase their work or 
constitute a burden: 
“I am coping and it’s only a few extra minutes with each patient 
and you only react on the abnormals and only on seeing the 
abnormality do you intervene with the medication. It’s also not 
every patient that is like that. May be there are a few 
hypertensives and may be then another diabetic, so it’s not a 
huge burden.” 
 
3a: Additional staff requirement for introducing the test 
 
All the respondents from the preparation room believed that 
additional staff would be required if the test was introduced as 
it added to their already busy schedule because the only nurse 
in the preparation room was already overworked: 
“It is possible if there are more staff because we are sitting 
with plus or minus 600 diabetic patients in total and for one 
nurse in the prep room to do it for all those patients is not 
possible.” 
 
3b: Additional staff requirement for interpreting and acting on 
the results 
 
Participants in this category believed they do not need 
additional staff because of the microalbuminuria test: 
“With us we are fine because it doesn’t take much time to talk 
to the patient and put the patient on the new treatment but it 
could be more time consuming in the preparation room but not for 
us, its okay with us we don’t need any additional staff.” 
 
4: Other issues relevant to the testing and intervention 
 
One of the participants acting on the result also raised the 
question of certain patients with allergy to Enalapril to which 
the doctor responded: 
“We are actually in the process of submitting a motivation for 
Lorsatan to be prescribed in place of Enalapril in instances 
where we have adverse reactions or side effects that prevent the 
patient from taking the Enalapril.” 
 
 
Discussion 
This study represents the first attempt to assess the 
feasibility of introducing microalbuminuria screening in 
diabetic patients to public sector primary health care in South 
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Africa. Microalbuminuria screening was successfully introduced 
into the care of diabetic patients at Elsies River CHC. Under 
normal working conditions the study found that if 100 patients 
were screened then 12 patients would be diagnosed with 
macroalbuminuria, another 15 diagnosed with microalbuminuria and 
it will cost the health system an additional R1225.50 to screen 
for and treat these patients in the first month. The cost of 
identifying a patient with microalbuminuria was R73.96 and the 
cost of treating a patient with the ACEI Enalapril per month was 
R7.74. The total cost therefore of identifying and treating one 
patient for one year with microalbuminuria in this health centre 
was R154.40. It should be noted that screening was completed in 
only 56.2% of all patients with a positive first test in this 
CHC, but almost all patients who were diagnosed received 
intervention. 
Staff found the testing and intervention easy and feasible to 
integrate into their daily routine. Although it only took an 
extra two minutes to perform the test, staff in the preparation 
room felt that additional staff capacity would be needed if this 
test became part of the normal protocol. Alternatively other 
unnecessary tasks could be stopped to increase the capacity of 
existing staff.  
It was generally observed that the screening can be introduced 
into the primary health care context with sufficient 
reliability. Approximately 56.2% of the eligible patients 
completed the screening process, when this is compared with data 
from the other routine annual investigations like serum 
creatinine (66.1%), HbA1c(57.9) and cholesterol(64.0%) which are 
only one time screening, it is a comparable result.  
Screening and prompt treatment with an ACEI leads to a gain in 
Quality Adjusted Life Years (QALY) and 88.9% of diagnosed 
patients received the benefit of increased ACEI therapy.(43) 
Stricter glycaemic and blood pressure control, lipid lowering 
therapy, dietary and weight control education were other 
interventions that were instituted as a direct response to a 
positive result. These interventions should be instituted in the 
normal day to day care of patients with type 2 diabetes 
irrespective of microalbuminuria however positivity for 
microalbuminuria is a red flag that these need to be carried out 
more intensively. Screening for microalbuminuria followed by 
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optimized interventions is found to lead to a 44% reduction in 
cumulative incidence of end stage renal disease (ESRD), the 
benefits of which are noted from two years after commencement of 
screening and intervention.(9) Although the effect of the health 
education is likely to be small, especially if it is a once off 
intervention, the benefits of intensified treatment should be 
long term. Based on the literature it is anticipated that there 
should be better clinical outcomes such as reduced incidence of 
ESRD and its associated reduction in cardiovascular complication 
as well as improved life expectancy and quality adjusted life 
expectancy, if these patients are followed up long term.(9) 
Diabetes is one of the commonest causes of kidney failure 
accounting for 44% new cases (47) and 40% of patients with 
diabetes are likely to develop nephropathy.(23) By extrapolation 
this is 40% of 1-1.5 million patients living with diabetes in 
South Africa.(4) In the current budget it is not possible to 
dialyse or transplant all of these patients and many are left 
untreated to die of ESRD. Investment in early screening and 
treatment may therefore be the only viable strategy to prevent 
premature deaths. The projected ESRD related costs for this 
population are shocking. In Tygerberg Hospital (TBH) the average 
annual cost of dialysis per patient is R120,000.00 and about 
R78,000.00 is spent yearly on every transplanted patient 
(personal communication with Prof Moosa and Prof Razeen Davids, 
Nephrology Unit, Department of Medicine TBH). It is difficult to 
quantify the cost of recurrent cardiovascular complications and 
repeated hospitalisations prior to dialysis and transplantation. 
One must also keep in mind the cost to the government of 
disability grants that are also paid to patients with ESRD. 
Nevertheless it is evident that the cost of treating one patient 
with dialysis for one year is at least the equivalent cost of 
screening 3000 diabetic patients and treating 450 patients at 
risk of renal disease, who would be identified, for at least 24 
months. In this context, early identification and immediate 
treatment has a potential to have a huge economic savings with 
substantial clinical gains and improved quality of life. Money 
is not always the most significant component of cost as future 
life years have a value that is difficult to quantify.  
The evidence base for cost savings and clinical benefits of 
screening for microalbuminuria as well as the intervention is 
very sound. A multinational review of evidence concluded that 
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screening for microalbuminuria and many other interventions 
intended to control for diabetes and its complications are cost 
saving and very cost effective and they are supported by strong 
evidence, policy makers should consider giving these 
interventions a higher priority.(48) 
Strengths and limitations 
The results are clearly influenced by the motivation and 
performance levels of the staff and degree of organisation 
within the CHC chosen. Here the motivation and performance 
appeared quite high as indicated by 100% of patients receiving 
the initial tests. The results represent the likely effect of 
screening under these normal working conditions and performance 
might be worse in CHCs with a more chaotic organizational 
framework or de-motivated staff. It is difficult therefore to 
generalize performance to the district or province as a whole. 
The possibility of a false positive result due to initial staff 
mistakes could not be ruled out despite taking all the necessary 
precautions to prevent it and this could lead to unnecessary 
intervention and attendant cost as well as worry for the 
patient.  
The qualitative data was collected by the researcher who might 
have been perceived by the health workers as having a vested 
interest in a more positive viewpoint and who was also 
responsible for analysing and interpreting the data.  
 
Recommendations 
The demonstrated feasibility of testing in the current system, 
small relative cost, likely long terms benefits to patients and 
future cost savings, make the introduction of testing for 
microalbuminuria in public sector primary care a recommendation 
of this study. Attention should be given to adequate capacity in 
the preparation room. Future research should focus on long term 
follow up of patients on interventions in order to be able to 
chart the impacts of the interventions on an individual patient 
and calculate the exact QALYs gained in our setting. 
 
Conclusion 
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This study demonstrated that it is feasible to introduce 
microalbuminuria testing into routine chronic care of diabetic 
patients in a public sector primary care facility. The immediate 
additional costs of screening and treating are overshadowed by 
the anticipated short term reduction in cardiovascular events 
and the avoidance of long term end stage renal disease. The 
benefit to the patients in terms of quality of life, and to the 
government in terms of future savings make this a cost-effective 
intervention. 
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HEALTH WORKER INFORMATION LEAFLET AND CONSENT 
FORM 
 
Is screening for microalbuminuria in Type 2 Diabetic patients feasible in the public sector primary care 
context? A cost and consequence study in two Community Health Centres. 
 
REFERENCE NUMBER: 
 
PRINICIPAL INVESTIGATOR: Prof RJ Mash 
 
CO-INVESTIGATORS: Dr H.O  Ibrahim and Dr D Stapar 
. 
ADDRESS: Family Medicine and Primary Care, Stellenbosch University, Box 19063, Tygerberg, 7505 
 
CONTACT NUMBER: 021 938 9061 / 9449 / 9170 
 
 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is very important that you are 
fully satisfied that you clearly understand what this research entails and how you could be involved. Also, 
your participation is entirely voluntary and you are free to decline to participate. If you say no, this will not 
affect you negatively in any way whatsoever. You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University and will be 
conducted according to the ethical guidelines and principles of the international Declaration of Helsinki, 
South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
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What is this research study all about? 
The study aims to assess how practical and affordable it is for a typical community health centre to 
implement testing for microalbuminuria in diabetic patients.  
 
Why have you been invited to participate? 
You have been invited to participate because, as a member of the chronic care team at your community 
health centre, you may have experience of testing patients for microalbuminuria, interpreting the results, 
deciding on what to do next and explaining the results to patients. 
 
What will your responsibilities be? 
You will be responsible to meet with the researcher when they visit the site to discuss any practical 
difficulties or clinical uncertainties related to the test. Your feedback on your experience will be recorded as 
part of the research study. The researcher will visit weekly in the first month, fortnightly in the next 2 
months and then monthly thereafter for the 12 month duration of the study. You should also contact the 
researcher by telephone at any time if you have any questions when using the test. 
 
You will be responsible for ensuring that if/when you are personally involved in microalbuminuria testing 
that you follow the standard operating procedures for the test, the interpretation and any subsequent 
interventions as provided by the research study during training. 
 
Will you benefit from taking part in this research? 
The study will help policy makers and managers in the District Health Services decide whether it is practical 
and affordable to introduce this test at all community health centres. 
 
Are there in risks involved in your taking part in this research? 
There are no risks to you personally.  
 
If you do not agree to take part, what alternatives do you have? 
Your health centre will have made a collective decision to take part in the study and your role in the testing 
will be clarified by the facility manager and family physician. You do not have to agree to be interviewed and 
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can also withdraw your consent for this at any time. 
 
Will you be paid to take part in this study and are there any costs involved? 
There are no costs for you and you will not be paid to take part. 
Is there any thing else that you should know or do? 
 You can contact Prof RJ Mash at 0723419542 or 021 938 9061 or your local researcher if you have 
any further queries or encounter any problems. 
 You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
 
By signing below, I…………………………………………………  agree to take part in  a research study  entitled:- Is 
screening for microalbuminuria in Type 2 Diabetic patients feasible in the public sector primary care 
context? A cost and consequence study in two Community Health Centres. 
 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to take part. 
 I may choose to leave the study at any time and will not be penalisd or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at  (place)…………………………..on (date) ……………………………….. 2004 
 
 
…………………………..                                                        ……………………… 
Signature  of Participant                                                       Signature of Witness.  
 
 
 
36 | P a g e  
 
Declaration By Investigator 
I  (name )  …………………………………………………declare that:- 
 
 I explained the information in this document to …………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
 I did/did not use a translator. (If a translator is used then the translator must sign the declaration 
below. 
 
Signed at  (place)…………………………..on (date) ……………………………….. 2004 
 
 
…………………………..                                                        ……………………… 
Signature  of Investigator                                                     Signature of Witness.  
 
 
 
 
 
 
 
 
